Stock of the Day

March 17, 2021

Penumbra (PEN)

$318.51
-$1.09 (-0.3%)
Market Cap: $12.57B

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Today's Trend

Penumbra, Inc. (PEN) — shares are trading higher after the company released Q4 and full‑year 2025 results and accompanying market and product news that investors view as supportive of growth. Below are the key items likely driving the move and how they may affect the stock.

  • Q4 results beat consensus: Penumbra reported $1.18 EPS vs. $1.12 expected and revenue of $385.4M vs. $367.2M est., with revenue up ~22% year‑over‑year and healthy margins/ROE — a clear near‑term fundamental catalyst supporting the rally. Penumbra Q4 and FY2025 Results
  • Analyst/coverage writeups emphasize the beat and bullish tone on the quarter — additional media amplification likely amplified buying interest. Penumbra Reports Bullish Q4
  • Product pipeline expansion: a new class of coils for treating pelvic venous disease highlights incremental TAM expansion beyond core thrombectomy products, supporting longer‑term growth expectations. New Coils for Pelvic Venous Disease
  • Intraday trading halt: PEN was temporarily halted for “News pending” around the quarter release — standard procedure that can exaggerate volatility but not a directional signal by itself.
  • Street sentiment mixed: coverage aggregate shows an average analyst rating of "Hold," which may limit upside if analyst revisions aren’t strongly positive post‑print. Analyst Ratings Summary
  • Valuation considerations: PEN trades at a high P/E (~75x) vs. growth expectations — strong results help justify the multiple, but elevated valuation makes the stock sensitive to any slowdown or weaker guidance.

Bottom line for investors: the EPS/revenue beat and product pipeline news are the primary positive drivers of today’s move, amplified by media coverage. Offsetting risks include a mixed analyst stance and a rich valuation that could increase short‑term volatility if guidance or forward commentary disappoints. Monitor management commentary on guidance and adoption of new products for confirmation of sustained upside.

← Previous Stock of the DayNext Stock of the Day →

Recent News